uniQure N.V. (NASDAQ:QURE - Get Free Report)'s share price was down 6.5% during trading on Friday . The stock traded as low as $13.99 and last traded at $14.11. Approximately 1,117,485 shares changed hands during mid-day trading, a decline of 42% from the average daily volume of 1,932,323 shares. The stock had previously closed at $15.10.
Wall Street Analyst Weigh In
Several equities research analysts have weighed in on QURE shares. HC Wainwright reiterated a "buy" rating and issued a $70.00 target price on shares of uniQure in a report on Thursday, May 29th. Chardan Capital reiterated a "buy" rating and issued a $38.00 target price on shares of uniQure in a report on Friday, May 30th. Wells Fargo & Company lowered their target price on uniQure from $35.00 to $30.00 and set an "equal weight" rating for the company in a report on Friday, February 28th. Wall Street Zen cut uniQure from a "hold" rating to a "sell" rating in a report on Saturday, June 14th. Finally, Guggenheim reiterated a "buy" rating and issued a $28.00 target price on shares of uniQure in a report on Monday, May 12th. One analyst has rated the stock with a sell rating, three have given a hold rating, six have given a buy rating and two have assigned a strong buy rating to the company's stock. According to data from MarketBeat, uniQure currently has a consensus rating of "Moderate Buy" and a consensus target price of $37.82.
View Our Latest Research Report on uniQure
uniQure Stock Performance
The business has a 50 day simple moving average of $14.20 and a 200 day simple moving average of $13.84. The company has a quick ratio of 11.99, a current ratio of 11.99 and a debt-to-equity ratio of 1.53. The company has a market capitalization of $778.42 million, a PE ratio of -3.24 and a beta of 0.08.
uniQure (NASDAQ:QURE - Get Free Report) last released its quarterly earnings results on Friday, May 9th. The biotechnology company reported ($0.82) EPS for the quarter, beating analysts' consensus estimates of ($1.07) by $0.25. uniQure had a negative return on equity of 483.87% and a negative net margin of 1,077.05%. The company had revenue of $1.57 million during the quarter, compared to analysts' expectations of $5.93 million. Equities research analysts predict that uniQure N.V. will post -3.75 EPS for the current fiscal year.
Insider Buying and Selling at uniQure
In other news, insider Jeannette Potts sold 4,670 shares of the firm's stock in a transaction dated Monday, June 16th. The stock was sold at an average price of $15.14, for a total value of $70,703.80. Following the completion of the transaction, the insider now directly owns 115,073 shares in the company, valued at $1,742,205.22. This trade represents a 3.90% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 4.79% of the stock is currently owned by company insiders.
Institutional Inflows and Outflows
Several institutional investors have recently modified their holdings of the company. Vestal Point Capital LP raised its stake in shares of uniQure by 58.4% in the first quarter. Vestal Point Capital LP now owns 4,792,572 shares of the biotechnology company's stock worth $50,801,000 after purchasing an additional 1,767,572 shares during the last quarter. Nantahala Capital Management LLC grew its holdings in uniQure by 3.8% during the first quarter. Nantahala Capital Management LLC now owns 2,755,962 shares of the biotechnology company's stock worth $29,213,000 after acquiring an additional 101,598 shares during the period. Aberdeen Group plc grew its holdings in uniQure by 46.8% during the first quarter. Aberdeen Group plc now owns 2,215,551 shares of the biotechnology company's stock worth $23,485,000 after acquiring an additional 706,216 shares during the period. Avoro Capital Advisors LLC acquired a new stake in uniQure during the fourth quarter worth about $38,410,000. Finally, Franklin Resources Inc. grew its holdings in uniQure by 33.1% during the fourth quarter. Franklin Resources Inc. now owns 1,987,688 shares of the biotechnology company's stock worth $35,103,000 after acquiring an additional 494,726 shares during the period. 78.83% of the stock is currently owned by hedge funds and other institutional investors.
uniQure Company Profile
(
Get Free Report)
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.
Further Reading
Before you consider uniQure, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and uniQure wasn't on the list.
While uniQure currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
